Michael August Blazing, MD

Associate Professor of Medicine
Campus mail 7412HOSP North, Durham, NC 27710
Phone (919) 681-3945
Email address blazi001@mc.duke.edu

General focus: My research interests are in primary and secondary prevention of cardiovascular disease. Specifically, I am looking at compliance issues within the cardiology division and in the University as a whole with regard to evidence based treatment and secondary prevention of cardiovascular disease. I am using both retrospective and prospective collection of discharge data to try and analyze these trends. In the future, we hope to begin clinical trials with regard to various issues which are outstanding in primary and secondary prevention. Some of the issues include treatment of hypercholesterolemia in elderly patients, differences between the various statins with regard to affects on lipid profiles, and early treatment of hypercholesterolemia after MI.

As part of my work, I have served as a consultant with various drug companies with regard to focusing on active issues and treatment of hypercholesterolemia.

Key words: Primary prevention, secondary prevention, hyperlipidemia, homocysteine, and hypertension.

In Their Words

Education and Training

  • M.D., University of California, San Francisco, School of Medicine, 1987

Publications

Qamar, A., R. P. Giugliano, E. A. Bohula, J. G. Park, P. Jarolim, S. A. Murphy, M. A. Blazing, et al. “Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial.” Journal of the American College of Cardiology 74, no. 8 (August 27, 2019): 1057–68. https://doi.org/10.1016/j.jacc.2019.06.038.

Full Text

Bach, Richard G., Christopher P. Cannon, Robert P. Giugliano, Jennifer A. White, Yuliya Lokhnygina, Erin A. Bohula, Robert M. Califf, Eugene Braunwald, and Michael A. Blazing. “Effect of Simvastatin-Ezetimibe Compared With Simvastatin Monotherapy After Acute Coronary Syndrome Among Patients 75 Years or Older: A Secondary Analysis of a Randomized Clinical Trial..” Jama Cardiol, July 17, 2019. https://doi.org/10.1001/jamacardio.2019.2306.

PMID
31314050
Full Text

Sharma, Abhinav, Jie-Lena Sun, Yuliya Lokhnygina, Matthew T. Roe, Tariq Ahmad, Nihar R. Desai, and Michael A. Blazing. “Patient Phenotypes, Cardiovascular Risk, and Ezetimibe Treatment in Patients After Acute Coronary Syndromes (from IMPROVE-IT)..” Am J Cardiol 123, no. 8 (April 15, 2019): 1193–1201. https://doi.org/10.1016/j.amjcard.2019.01.034.

PMID
30739657
Full Text

Cholesterol Treatment Trialists’ Collaboration, Justin P. “Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials..” Lancet 393, no. 10170 (February 2, 2019): 407–15. https://doi.org/10.1016/S0140-6736(18)31942-1.

PMID
30712900
Full Text

Navar, Ann Marie, Matthew T. Roe, Jennifer A. White, Christopher P. Cannon, Yuliya Lokhnygina, L Kristin Newby, Robert P. Giugliano, et al. “Medication Discontinuation in the IMPROVE-IT Trial..” Circ Cardiovasc Qual Outcomes 12, no. 1 (January 2019). https://doi.org/10.1161/CIRCOUTCOMES.118.005041.

PMID
30630361
Full Text

Fudim, Marat, Arun Ganesh, Cindy Green, W Schuyler Jones, Michael A. Blazing, Adam D. DeVore, G Michael Felker, et al. “Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF..” Eur Heart J 39, no. 48 (December 21, 2018): 4255–56. https://doi.org/10.1093/eurheartj/ehy682.

PMID
30346508
Full Text

Bonaca, Marc P., J Antonio Gutierrez, Christopher Cannon, Robert Giugliano, Michael Blazing, Jeong-Gun Park, Jennifer White, Andrew Tershakovec, and Eugene Braunwald. “Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial..” Lancet Diabetes Endocrinol 6, no. 12 (December 2018): 934–43. https://doi.org/10.1016/S2213-8587(18)30290-0.

PMID
30396865
Full Text

Simon, Tracey G., Kathleen E. Corey, Christopher P. Cannon, Michael Blazing, Jeong-Gun Park, Michelle L. O’Donoghue, Raymond T. Chung, and Robert P. Giugliano. “The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe..” Int J Cardiol 270 (November 1, 2018): 245–52. https://doi.org/10.1016/j.ijcard.2018.05.087.

PMID
29903515
Full Text

Ambrosy, Andrew P., Lukasz P. Cerbin, Marat Fudim, Robert M. Clare, Yuliya Lokhnygina, Eugene Braunwald, Robert M. Califf, et al. “Natural History of Patients Postacute Coronary Syndrome Based on Heart Failure Status..” Am J Cardiol 122, no. 9 (November 1, 2018): 1451–58. https://doi.org/10.1016/j.amjcard.2018.07.034.

PMID
30180960
Full Text

Yang, Shu, Anastasios A. Tsiatis, and Michael Blazing. “Modeling survival distribution as a function of time to treatment discontinuation: A dynamic treatment regime approach..” Biometrics 74, no. 3 (September 2018): 900–909. https://doi.org/10.1111/biom.12845.

PMID
29359317
Full Text

Pages